Abdelrahim O Mohamed1, Maazza Hussien2,3, Amal Mohamed4, Abdelmaroof Suliman5, Nuha S Elkando5, Hanadi Abdelbagi3, Elfatih M Malik6, Mohammed H Abdelraheem3, Muzamil Mahdi Abdel Hamid7,8. 1. Department of Biochemistry, Faculty of Medicine, University of Khartoum, Khartoum, Sudan. abdelrahim_osman@yahoo.com. 2. Department of Medical Parasitology and Entomology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan. 3. Institute of Endemic Diseases, Medical Campus, University of Khartoum, P. O. Box 102, Khartoum, Sudan. 4. Department of Accreditation, General Directorate of Quality, Development and Accreditation, Khartoum, Sudan. 5. State Ministry of Health, Blue Nile State, Damazin, Sudan. 6. Department of Community Medicine Faculty of Medicine, University of Khartoum, Khartoum, Sudan. 7. Department of Medical Parasitology and Entomology, Faculty of Medical Laboratory Sciences, Al Neelain University, Khartoum, Sudan. mahdi@iend.org. 8. Institute of Endemic Diseases, Medical Campus, University of Khartoum, P. O. Box 102, Khartoum, Sudan. mahdi@iend.org.
Abstract
BACKGROUND: Plasmodium falciparum malaria is a public health problem worldwide. Malaria treatment policy has faced periodic changes due to emergence of drug resistant parasites. In Sudan chloroquine has been replaced by artesunate and sulfadoxine/pyrimethamine (AS/SP) in 2005 and to artemether-lumefantrine (AL) in 2017, due to the development of drug resistance. Different molecular markers have been used to monitor the status of drug resistant P. falciparum. This study aimed to determine the frequency of malaria drug resistance molecular markers in Southeast Sudan. METHODS: The samples of this study were day zero dried blood spot samples collected from efficacy studies in the Blue Nile State from November 2015 to January 2016. A total of 130 samples were amplified and sequenced using illumina Miseq platform. The molecular markers included were Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, Pfk13, exonuclease and artemisinin resistant (ART-R) genetic background (Pfmdr2, ferroredoxine, Pfcrt and Pfarps10). RESULTS: Resistance markers for chloroquine were detected in 25.8% of the samples as mutant haplotype Pfcrt 72-76 CVIET and 21.7% Pfmdr1 86Y. Pfdhfr mutations were detected in codons 51, 59 and 108. The ICNI double-mutant haplotype was the most prevalent (69%). Pfdhps mutations were detected in codons 436, 437, 540, 581 and 613. The SGEGA triple-mutant haplotype was the most prevalent (43%). In Pfdhfr/Pfdhps combined mutation, quintuple mutation ICNI/SGEGA is the most frequent one (29%). Six of the seven treatment failure samples had quintuple mutation and the seventh was quadruple. This was significantly higher from the adequately responsive group (P < 0.01). Pfk13 novel mutations were found in 7 (8.8%) samples, which were not linked to artemisinin resistance. Mutations in ART-R genetic background genes ranged from zero to 7%. Exonuclease mutation was not detected. CONCLUSION: In this study, moderate resistance to chloroquine and high resistance to SP was observed. Novel mutations of Pfk13 gene not linked to treatment failure were described. There was no resistance to piperaquine the partner drug of dihydroartemisinin/piperaquine (DHA-PPQ).
BACKGROUND: <span class="Species">Plasmodium falciparummalaria is a public health problem worldwide. Malaria treatment policy has faced periodic changes due to emergence of drug resistant parasites. In Sudan chloroquine has been replaced by artesunate and sulfadoxine/pyrimethamine (AS/SP) in 2005 and to artemether-lumefantrine (AL) in 2017, due to the development of drug resistance. Different molecular markers have been used to monitor the status of drug resistant P. falciparum. This study aimed to determine the frequency of malaria drug resistance molecular markers in Southeast Sudan. METHODS: The samples of this study were day zero dried blood spot samples collected from efficacy studies in the Blue Nile State from November 2015 to January 2016. A total of 130 samples were amplified and sequenced using illumina Miseq platform. The molecular markers included were Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, Pfk13, exonuclease and artemisinin resistant (ART-R) genetic background (Pfmdr2, ferroredoxine, Pfcrt and Pfarps10). RESULTS: Resistance markers for chloroquine were detected in 25.8% of the samples as mutant haplotype Pfcrt 72-76 CVIET and 21.7% Pfmdr1 86Y. Pfdhfr mutations were detected in codons 51, 59 and 108. The ICNI double-mutant haplotype was the most prevalent (69%). Pfdhps mutations were detected in codons 436, 437, 540, 581 and 613. The SGEGA triple-mutant haplotype was the most prevalent (43%). In Pfdhfr/Pfdhps combined mutation, quintuple mutation ICNI/SGEGA is the most frequent one (29%). Six of the seven treatment failure samples had quintuple mutation and the seventh was quadruple. This was significantly higher from the adequately responsive group (P < 0.01). Pfk13 novel mutations were found in 7 (8.8%) samples, which were not linked to artemisinin resistance. Mutations in ART-R genetic background genes ranged from zero to 7%. Exonuclease mutation was not detected. CONCLUSION: In this study, moderate resistance to chloroquine and high resistance to SP was observed. Novel mutations of Pfk13 gene not linked to treatment failure were described. There was no resistance to piperaquine the partner drug of dihydroartemisinin/piperaquine (DHA-PPQ).
Authors: Ishraga E A-Elbasit; Mustafa I Elbashir; Insaf F Khalil; Michael Alifrangis; Hayder A Giha Journal: Trop Med Int Health Date: 2006-05 Impact factor: 2.622
Authors: Kevin Galinsky; Clarissa Valim; Arielle Salmier; Benoit de Thoisy; Lise Musset; Eric Legrand; Aubrey Faust; Mary Lynn Baniecki; Daouda Ndiaye; Rachel F Daniels; Daniel L Hartl; Pardis C Sabeti; Dyann F Wirth; Sarah K Volkman; Daniel E Neafsey Journal: Malar J Date: 2015-01-19 Impact factor: 2.979
Authors: Abdelrahim O Mohamed; Muzamil M Abdel Hamid; Omer S Mohamed; Nuha S Elkando; Abdelmaroof Suliman; Mariam A Adam; Fahad Awad Ali Elnour; Elfatih M Malik Journal: Malar J Date: 2017-04-20 Impact factor: 2.979
Authors: Maja Malmberg; Pedro E Ferreira; Joel Tarning; Johan Ursing; Billy Ngasala; Anders Björkman; Andreas Mårtensson; José P Gil Journal: J Infect Dis Date: 2012-12-05 Impact factor: 5.226
Authors: Sofia B Mohamed; Sumaya Kambal; Sabah A E Ibrahim; Esra Abdalwhab; Abdalla Munir; Arwa Ibrahim; Qurashi Mohamed Ali Journal: PLoS Comput Biol Date: 2021-10-21 Impact factor: 4.475